Research communicationProtection of the ischemic rat heart by Procysteine (cas 19771-63-2) and amino acids☆

Add time:09/02/2019    Source:sciencedirect.com

This study was conducted to determine the efficacy of amino acids and/or Procysteine (cas 19771-63-2) (Clintec Technologies, Inc., Deerfield, IL, USA) on the recovery of cardiac function of the rat heart subjected to ischemia/reperfusion. Recovery of myocardium following ischemia/reperfusion is affected by both oxidative stress associated with depletion of glutathione and depletion of mitochondrial substrates. Procysteine maintains cellular levels of glutathione; amino acid supplies substrates for mitochondria. The model was the in vitro rat heart subjected to global no-flow ischemia and reperfused. Controls were perfused with buffer. End points were several hemodynamic parameters. Procysteine was maximally effective at 250 and 500 μmol/L (41% recovery of cardiac output). At 40 minutes post-no-flow ischemia, recovery of cardiac output was: controls, 11 ± 4%; 500 μmol/L Procysteine, 41 ± 10%; 0.25% amino acid, 34 ± 9%; Procysteine plus amino acid, 62 ± 10%. Other hemodynamic parameters were also enhanced. Kinetics of recovery differed between the two modes of treatment. Procysteine and amino acid, alone or in combination, improved recovery of rat hearts from ischemia/reperfusion injury; the effects were additive. The kinetics of recovery differ with the two modes of treatment. The low toxicity and good efficacy of Procysteine and amino acids suggest their use in treatment of the ischemic myocardium.

We also recommend Trading Suppliers and Manufacturers of Procysteine (cas 19771-63-2). Pls Click Website Link as below: cas 19771-63-2 suppliers

Prev:Bacterial mutagenicity of aceanthrylene: A novel cyclopenta-fused polycyclic aromatic hydrocarbon of low molecular weight
Next:Toxicity evaluations of l-cysteine and Procysteine (cas 19771-63-2)™, a cysteine prodrug, given once intravenously to neonatal rats)